ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib was the first specific BCR-ABL tyrosine kinase inhibitor (TKI) to be approved for the treatment of BCR-ABL+ ALL and CML and has led to a major breakthrough in the treatment of these malignancies.